AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies

INDIANAPOLIS, April 24, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today results from a post-hoc subgroup analysis which demonstrated efficacy of galcanezumab in patients with episodic and chronic migrain... Biopharmaceuticals, Neurology Eli Lilly, galcanezumab, migraine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news